determined. Then in subsequent experiments, cells were treated with serial dilutions of each drug individually and with both drugs simultaneously in a fixed molar ratio. The Calcusyn software (Biosoft, Cambridge, UK) was used to determine whether any synergy existed between the agents using the Chou and Talalay method [2] which takes into account both potency (effective dose 50) and the shape of the dose-effect curve. Accordingly, the combination index (CI) was calculated and analyzed as follows: CI<1, CI=1 and CI>1 indicate synergism, additive effect and antagonism, respectively.
Ex-vivo drug treatment
Cell lines were cultured in 6-well plates at 1. 10 6 cells/ml and were incubated in the control medium or with 1 µM JQ1, 1 µM SAHA, 10 nM Bortezomib or 50 nM Vincristine. At 24h, cells were harvested for western blot and RQ-PCR and at 48h for viability and cell cycle quantification. Drug treatments of human primary T-ALL were performed as for cell lines and were stopped after 24 H incubation for molecular analysis and for apoptosis assays. Inc.) overnight at 4°C with agitation. The secondary Anti-rabbit, -mouse or -goat antibodies (Santa Cruz Biotechnology) conjugated to HRP were added for 1 hour at room temperature.
Molecular and cellular analysis

Real-time Quantitative PCR (RQ-PCR
Immunoblots were revealed using ECL western blotting detection reagents (GE Healthcare) and stripped using Restore western blot stripping buffer (Pierce).
Cell apoptosis and cell cycle. Drugs were first distributed in a 96 wells plate in triplicate at 8 concentrations ranging from 100 µM to 10 -5 µM (except for Daunorubicin for which a range from 10 µM to 10 -6 µM was used), then DND-41 cells (1.10 5 /well) were added and plates were incubated at 37°C. After 72H, metabolic activity (reflecting cell growth and viability) was monitored by measuring intracellular ATP levels using CellTiter-Glo chemiluminescence reagent. This pre-screen was performed to define a narrow range of drug concentrations that will be used for the screen.
P R E -S C R E E N S C R E E N
Typically for the screen, drugs of interest are each used at 4 concentrations: 20 nM to 20 µM for most drugs; 2 nM to 2 µM for Daunorubicin and Vincristine; 0.2 nM to 0.2 µM for Bortezomib. Then, similarly to the pre-screen, drugs were distributed in a 96 wells plate and were incubated for 72H with ~1.10 5 cells of choice. Finally, samples were analyzed using CellTiter-Glo kit and the concentration for which 50% of the cells were affected (EC 50 ) was determined for each drugs. In the control wells, cells were incubated with culture media supplemented with 5% DMSO. 
